Qorvo Biotechnologies is developing a point-of-care (POC) diagnostic testing platform that aims to change how healthcare is provided. Our developmental system is based on high performance bulk acoustic wave (BAW) detection, designed with the goal to provide accurate, central lab equivalent results within 10-15 minutes.
The Qorvo testing platform is an investigational technology currently limited to investigational use and is not available for sale.
BAW enables surface-based mass measurement. Qorvo’s BAW technology uses high frequency and surface binding that, based on results of early stage feasibility studies, suggests the potential for sensitivity and variance control similar to central labs. These two factors have limited the ubiquitous deployment of point-of-care solutions based on historical optical or fluorescence detection systems. The innovation is uniquely positioned to allow for the dual testing capability of Molecular and Immunoassays on the same cartridge and instrument interface. Beyond this, BAW allows for multiplexing (multiple analytes tested off a single sample), and the cartridge has been designed to allow measurements of multiple matrix types including whole blood, serum, plasma, saliva and more. The goal is to enable clinicians’ access to point-of-care test data in minutes.
White Paper: Qorvo Biotechnologies Sensor-based Technology Aims to Provide Rapid Reference-Lab Quality Tests at the Point-of-Care
Press Release: Qorvo Point-of-Care Diagnostic Platform Achieves Key Development Milestone
Press Release: Zomedica Completes Verification of its TRUFORMA Point-of-Care Diagnostic Platform and the First Assay Canine total T4
Press Release: Find Explores New Diagnostic Technologies with the Potential to Confirm Hepatitis C Infection in Community Settings
Press Release: Zomedica Signs Exclusive Agreement with Qorvo Biotechnologies for Global Veterinary Rights to Diagnostic Point-of-Care Platform